Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of MenABCWY Vaccine in Adolescents
NCT04502693Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2020
- Primary completion
- Sep 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of pexidartinib in meningococcal infection (6 arms), sponsored by GSK. Primary endpoints: Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains, Percentage of Participants Whose Sera Kill >= 70% of the Strains Tested Using Enc-hSBA and 4 more. Started Aug 2020; status: completed.
02
Drugs
pexidartinib
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT04502693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04502693.